NASDAQ:CRGX CARGO Therapeutics (CRGX) Stock Price, News & Analysis $4.57 +0.03 (+0.66%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CARGO Therapeutics Stock (NASDAQ:CRGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CARGO Therapeutics alerts:Sign Up Key Stats Today's Range$4.44▼$4.6550-Day Range$3.64▼$4.6452-Week Range$3.00▼$25.45Volume1.27 million shsAverage Volume511,921 shsMarket Capitalization$210.46 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingReduce Company OverviewCARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.Read More… CARGO Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreCRGX MarketRank™: CARGO Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 417th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingReduce Consensus RatingCARGO Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageCARGO Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CARGO Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CARGO Therapeutics are expected to grow in the coming year, from ($3.69) to ($2.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CARGO Therapeutics is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CARGO Therapeutics is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCARGO Therapeutics has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about CARGO Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CRGX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCARGO Therapeutics does not currently pay a dividend.Dividend GrowthCARGO Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for CRGX. News and Social Media2.7 / 5News SentimentN/A News SentimentCARGO Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for CARGO Therapeutics this week, compared to 3 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CARGO Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.38% of the stock of CARGO Therapeutics is held by insiders.Percentage Held by Institutions93.16% of the stock of CARGO Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CARGO Therapeutics' insider trading history. Receive CRGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CARGO Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CRGX Stock News HeadlinesIs CARGO Therapeutics (NASDAQ:CRGX) In A Good Position To Deliver On Growth Plans?March 27, 2025 | finance.yahoo.comCargo suspends CRG-023 and allogeneic platform, reduces workforce by 90%March 20, 2025 | markets.businessinsider.comDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retirement" process . This fired the starting gun on the biggest economic transformation in American history.April 30, 2025 | Altimetry (Ad)CARGO Therapeutics Stock (NASDAQ:CRGX) Jumps 20% on Buyout HopesMarch 19, 2025 | markets.businessinsider.comCargo Therapeutics, Inc.: CARGO Therapeutics Provides Corporate UpdateMarch 19, 2025 | finanznachrichten.deCargo Therapeutics Ceases More Treatment Development, Cuts 90% of JobsMarch 18, 2025 | marketwatch.comCARGO Therapeutics rises after hours on workforce reductionMarch 18, 2025 | msn.comCARGO Therapeutics Provides Corporate UpdateMarch 18, 2025 | globenewswire.comSee More Headlines CRGX Stock Analysis - Frequently Asked Questions How have CRGX shares performed this year? CARGO Therapeutics' stock was trading at $14.42 on January 1st, 2025. Since then, CRGX shares have decreased by 68.2% and is now trading at $4.59. View the best growth stocks for 2025 here. How were CARGO Therapeutics' earnings last quarter? CARGO Therapeutics, Inc. (NASDAQ:CRGX) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.26. When did CARGO Therapeutics IPO? CARGO Therapeutics (CRGX) raised $281 million in an initial public offering on Friday, November 10th 2023. The company issued 18,750,000 shares at a price of $15.00 per share. Who are CARGO Therapeutics' major shareholders? CARGO Therapeutics' top institutional investors include Peapod Lane Capital LLC (0.48%), Bank of New York Mellon Corp (0.21%) and Rhumbline Advisers (0.10%). Insiders that own company stock include Samsara Biocapital Gp, Llc, Perceptive Advisors Llc, Gina Chapman and Anup Radhakrishnan. View institutional ownership trends. How do I buy shares of CARGO Therapeutics? Shares of CRGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CARGO Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CARGO Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings11/12/2024Today4/30/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRGX Previous SymbolNASDAQ:CRGX CIK1966494 Webcargo-tx.com Phone650-379-6143FaxN/AEmployees116Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$33.00 Low Stock Price Target$3.00 Potential Upside/Downside+230.4%Consensus RatingReduce Rating Score (0-4)1.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,150,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.16% Return on Assets-33.94% Debt Debt-to-Equity RatioN/A Current Ratio18.94 Quick Ratio18.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.84 per share Price / Book0.46Miscellaneous Outstanding Shares46,052,000Free Float45,393,000Market Cap$209.08 million OptionableN/A Beta0.66 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CRGX) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CARGO Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CARGO Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.